Quantcast

Industry news that matters to you.  Learn more

GenePool from Station X to Help Epic Sciences Analyze Circulating Tumor Cell Data

Station X, Inc., a pioneer in solving big data analytics and platform integration challenges for customers engaging in genomics-based clinical research and medical applications, recently announced that Epic Sciences will use its GenePool® platform to facilitate data interpretation and collaboration with biopharmaceutical companies developing companion diagnostics based on the company’s innovative circulating tumor cell (CTC) technology.

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient’s blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

Researchers Report ScreenCell Usage for Colorectal Cancer – CTC Biomarker

In a recent paper, Cancer Biomarkers (Cancer Biomarkers 14 (2014) p.145–150), researchers at Rouen University Hospital, Rome University Hospital-La Sapienza, and University of Medicine and Pharmacy, Cluj-Napoca, Romania report on the use of the ScreenCell Cyto device to capture and characterize Circulating Tumor Cells (CTCs) from patients with colorectal cancer (CRC). This is the first preliminary report on the use of ScreenCell with samples from CRC patients.

Discovery of Giant Macrophages in the Blood of Cancer Patients

Creatv MicroTech, Inc. collaborates with cancer researchers from a number of universities to study circulating tumor cells (CTCs) in the blood of cancer patients. When cancers become advanced, tumor cells from the primary tumor can enter the bloodstream and cause metastasis at another organ — such as liver, lung, bone, or the brain — with deadly effect. While researching the biological implications of CTC spread, Creatv’s research team found a group of previously unreported cells associated with primary cancer spread. These unusual cells were named “circulating cancer-associated macrophage-like cells” (CAMLs). Their very large size – 25 to 300 microns – stands out, and they have five different morphologies. Their biological implications were recently reported in Proceedings of the National Academy of Sciences.

New Study Shows Circulating Tumor Cell Enumeration – as Part of Composite Biomarker Panel – May Serve as a Surrogate for Efficacy Response in Metastatic Castration-Resistant Prostate Cancer

Janssen Diagnostics, LLC recently announced results from a study presented at the European Cancer Congress in Amsterdam, Netherlands, that demonstrated circulating tumor cell (CTC) enumeration using CELLSEARCH®, along with lactate dehydrogenase (LDH) as part of a composite biomarker panel, was an efficacy-response surrogate for survival in managing patients with metastatic castration-resistant prostate cancer (mCRPC). The results show mCRPC patients with greater than or equal to five CTCs and an abnormal LDH level at 12 weeks of treatment have a poorer prognosis than those with lower CTC counts and normal LDH values, with a one- and two-year survival probability of 25 percent and 2 percent compared to 82 percent and 46 percent, respectively. Findings suggest therapeutic alternatives should be considered for patients in the high-risk category at 12 weeks.